Prescient Therapeutics Ltd Asset Resilience Ratio
Prescient Therapeutics Ltd asset resilience ratio. Prescient Therapeutics Ltd (PTX) has an Asset Resilience Ratio of 52.86% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Prescient Therapeutics Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Prescient Therapeutics Ltd (2001–2025)
Asset resilience ratio of Prescient Therapeutics Ltd from 2001 to 2025. This chart shows how Prescient Therapeutics Ltd's Asset Resilience Ratio has changed over time. Read PTX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Prescient Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Prescient Therapeutics Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$9.75 Million | 52.74% |
| Short-term Investments | AU$20.97K | 0.11% |
| Total Liquid Assets | AU$9.77 Million | 52.86% |
Asset Resilience Insights
- Very High Liquidity: Prescient Therapeutics Ltd maintains exceptional liquid asset reserves at 52.86% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Prescient Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Prescient Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
Prescient Therapeutics Ltd Asset Resilience Ratio by Year (2001–2025)
Prescient Therapeutics Ltd asset resilience ratio by year from 2001 to 2025. The table below shows the annual Asset Resilience Ratio data for Prescient Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.14% | AU$20.00K ≈ $14.15K |
AU$14.56 Million ≈ $10.30 Million |
-49.00pp |
| 2024-06-30 | 49.13% | AU$10.02 Million ≈ $7.09 Million |
AU$20.39 Million ≈ $14.43 Million |
-22.09pp |
| 2023-06-30 | 71.22% | AU$20.02 Million ≈ $14.17 Million |
AU$28.11 Million ≈ $19.89 Million |
+71.11pp |
| 2022-06-30 | 0.11% | AU$20.00K ≈ $14.15K |
AU$17.62 Million ≈ $12.47 Million |
+0.02pp |
| 2021-06-30 | 0.10% | AU$20.00K ≈ $14.15K |
AU$20.97 Million ≈ $14.84 Million |
-0.07pp |
| 2020-06-30 | 0.17% | AU$20.00K ≈ $14.15K |
AU$12.07 Million ≈ $8.54 Million |
-64.20pp |
| 2019-06-30 | 64.37% | AU$9.66 Million ≈ $6.83 Million |
AU$15.01 Million ≈ $10.62 Million |
+9.26pp |
| 2018-06-30 | 55.11% | AU$5.51 Million ≈ $3.90 Million |
AU$9.99 Million ≈ $7.07 Million |
-7.57pp |
| 2017-06-30 | 62.68% | AU$7.67 Million ≈ $5.42 Million |
AU$12.23 Million ≈ $8.65 Million |
+1.71pp |
| 2005-06-30 | 60.96% | AU$2.55 Million ≈ $1.80 Million |
AU$4.18 Million ≈ $2.96 Million |
-27.03pp |
| 2004-06-30 | 87.99% | AU$3.65 Million ≈ $2.58 Million |
AU$4.15 Million ≈ $2.94 Million |
+20.66pp |
| 2003-06-30 | 67.34% | AU$1.10 Million ≈ $778.32K |
AU$1.63 Million ≈ $1.16 Million |
-14.68pp |
| 2002-06-30 | 82.02% | AU$1.56 Million ≈ $1.11 Million |
AU$1.90 Million ≈ $1.35 Million |
-8.15pp |
| 2001-06-30 | 90.16% | AU$3.86 Million ≈ $2.73 Million |
AU$4.28 Million ≈ $3.03 Million |
-- |
About Prescient Therapeutics Ltd
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to… Read more